Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes

DNA Cell Biol. 1999 Oct;18(10):731-41. doi: 10.1089/104454999314872.

Abstract

We used a genetic approach to characterize features of mitogen-activated protein kinase (MAPK) activation occurring as a consequence of expression of distinct erbB receptor combinations in transformed human cells. Kinase-deficient erbB proteins reduced epidermal growth factor (EGF)-induced tyrosine phosphorylation of endogenous Shc proteins and also reduced immediate and sustained EGF-induced ERK MAPK activities in human glioblastoma cells, although basal ERK MAPK activities were unaffected. Basal and EGF-induced JNK and p38 MAPK kinase activities were equivalent in parental cancer cells and EGFR-inhibited subclones. When ectopically overexpressed in murine fibroblasts and human glioblastoma cells, a constitutively activated human EGF receptor oncoprotein (deltaEGFR) induced EGF-independent elevation of basal ERK MAPK activity. Basal JNK MAPK kinase activity was also specifically induced by deltaEGFR, which correlated with increased phosphorylation of a 54-kDa JNK2 protein observed in deltaEGFR-containing cells. The JNK activities in response to DNA damage were comparably increased in cells containing wildtype EGFR or deltaEGFR. Consistent with the notion that transforming erbB complexes induce sustained and unregulated MAPK activities, coexpression of p185(neu) and EGFR proteins to levels sufficient to transform murine fibroblasts also resulted in prolonged EGF-induced ERK in vitro kinase activation. Transforming erbB complexes, including EGFR homodimers, deltaEGFR homodimers, and p185(neu)/EGFR heterodimers, appear to induce sustained, unattenuated activation of MAPK activities that may contribute to increased transformation and resistance to apoptosis in primary human glioblastoma cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adaptor Proteins, Signal Transducing*
  • Adaptor Proteins, Vesicular Transport*
  • Animals
  • Brain Neoplasms / enzymology
  • Brain Neoplasms / pathology
  • Cell Line, Transformed / drug effects
  • Cell Transformation, Neoplastic
  • DNA Damage
  • Dimerization
  • Enzyme Activation / drug effects
  • Epidermal Growth Factor / pharmacology
  • ErbB Receptors / genetics
  • ErbB Receptors / physiology*
  • Fibroblasts / drug effects
  • Fibroblasts / enzymology
  • Genes, erbB*
  • Glioblastoma / enzymology
  • Glioblastoma / pathology
  • Humans
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Signaling System* / genetics
  • Mice
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Mitogen-Activated Protein Kinases / metabolism
  • Neoplasm Proteins / metabolism*
  • Phosphorylation / drug effects
  • Protein Multimerization
  • Protein Processing, Post-Translational / drug effects
  • Protein Structure, Tertiary
  • Proteins / metabolism
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / physiology*
  • Recombinant Fusion Proteins / physiology
  • Sequence Deletion
  • Shc Signaling Adaptor Proteins
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • Transfection
  • Tumor Cells, Cultured / drug effects
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Adaptor Proteins, Signal Transducing
  • Adaptor Proteins, Vesicular Transport
  • Neoplasm Proteins
  • Proteins
  • Recombinant Fusion Proteins
  • SHC1 protein, human
  • Shc Signaling Adaptor Proteins
  • Shc1 protein, mouse
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • Epidermal Growth Factor
  • ErbB Receptors
  • Receptor, ErbB-2
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase Kinases